Adrenogenital syndrome treatment market seen rising to $16.95 billion by 2030

The global market for adrenogenital syndrome treatments is projected to grow from $13.56 billion in 2026 to $16.95 billion by 2030, driven by personalized medicine, genetic testing and broader access to care. North America held the largest share in 2025, while new report features focus on market hotspots, TAM analysis and forecasting tools.

Why it matters: - The adrenogenital syndrome treatment market is expanding as more patients gain access to diagnosis and therapy for a rare hereditary disorder that can cause dangerous hormone imbalances. - Growth in personalized hormone therapy and genetic testing could improve outcomes by making treatment more targeted and reducing complications such as adrenal crises and abnormal growth patterns.

What happened: - The Business Research Company published its Adrenogenital Syndrome Treatment Global Market Report 2026 covering market size, trends and a forecast through 2035. - The report says the market rose from $12.8 billion in 2025 to $13.56 billion in 2026. - The report projects the market will reach $16.95 billion by 2030. - The company also made a free sample available here. - A full version of the report is available here.

The details: - Historical growth was tied to limited availability of synthetic corticosteroids, rising awareness, expanding hospital and clinic infrastructure, more cases of congenital adrenal hyperplasia and wider use of oral and parenteral drug administration. - Future growth is expected to come from better genetic testing, stronger demand for personalized hormone therapies, more home care treatment use, new corticosteroid formulations and broader hospital and retail pharmacy networks. - The report highlights growing use of hormone replacement therapies tailored to individual patient needs. - Genetic testing is becoming more common for early diagnosis and faster intervention. - Mineralocorticoid and glucocorticoid therapies are expected to gain traction during the forecast period. - Home-based care and tighter patient monitoring are also becoming more important. - Adrenogenital syndrome is a hereditary adrenal gland disorder that disrupts cortisol and aldosterone levels. - Corticosteroids remain the primary treatment approach to restore hormonal balance and lower health risks.

Between the lines: - Personalized medicine is becoming a key commercial driver because it aligns treatment more closely with patient genetics, lifestyle and health needs. - The Personalized Medicine Coalition reported 16 FDA approvals for personalized treatments in 2023, up from six in 2022, signaling broader acceptance of the approach beyond cancer care. - North America held the largest market share in 2025, helped by advanced healthcare infrastructure, higher awareness and wider availability of innovative treatments. - The report also covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa, showing that the market is being tracked as a global growth category. - New report features include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated trend analysis.

What's next: - The market is expected to keep growing steadily as healthcare systems expand access to testing, home care and pharmacy distribution. - Continued advances in genetic testing and corticosteroid formulations are likely to shape the next phase of treatment development. - North America is expected to remain a major force in market growth through 2026 and beyond.

The bottom line: - Adrenogenital syndrome treatment is moving toward more personalized, more accessible care, and the market data points to steady expansion through 2030.